Chronic Neutrophilic Leukemia: Current and Future Perspectives

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic neutrophilic leukemia (CNL) is a BCR-ABL1-negative myeloproliferative neoplasm associated with poor prognosis.
• The 2016 World Health Organization classification aids in distinguishing CNL from overlapping myeloid neoplasms.
• Advances in next-generation sequencing are crucial for understanding CNL's molecular basis and treatment strategies.

Purpose of the Study:

• To provide a comprehensive review of the current classification, diagnostic criteria, and molecular pathogenesis of CNL.
• To discuss the therapeutic landscape of CNL, including established and emerging treatments.
• To highlight the role of targeted therapies in managing CNL based on its molecular profile.

Main Methods:

• Review of contemporary literature on Chronic Neutrophilic Leukemia.
• Analysis of diagnostic criteria based on the latest World Health Organization classifications.
• Examination of molecular pathogenesis through next-generation sequencing data.
• Discussion of therapeutic options, including hematopoietic stem-cell transplantation and targeted agents.

Main Results:

• The 2016 WHO classification provides clear diagnostic criteria for CNL.
• Next-generation sequencing has elucidated the molecular heterogeneity of CNL.
• Hematopoietic stem-cell transplantation is the current standard of care for curative treatment.
• Emerging targeted therapies, particularly JAK and MAPK pathway inhibitors, show therapeutic potential.

Conclusions:

• Accurate classification and molecular understanding are vital for managing CNL.
• Hematopoietic stem-cell transplantation remains the primary curative option.
• Targeted therapies offer promising new avenues for CNL treatment, addressing its molecular complexities.